Repligen (RGEN) traded lower Friday, down 3.22% to $110.74, with price action consistent with post-earnings expectation compression rather than a single new headline. No major same-day corporate announcement surfaced in the latest company communications, leaving the stock to trade on existing narratives around 2026 growth visibility and valuation sensitivity.

The key anchor for the tape remains Repligen’s Feb. 24, 2026 update, when the company reported Q4/full-year 2025 results and issued 2026 guidance. Repligen guided 2026 revenue of $810 million to $840 million and called for organic growth in the high single digits to low teens, alongside margin expansion expectations—an outlook that was viewed as conservative relative to prior buyside positioning and has kept investors quick to sell into rallies. (investors.repligen.com)

Adding to the pressure, analysts have reduced price targets in the wake of the February guidance, reinforcing the idea that near-term upside may be capped until demand acceleration becomes clearer. UBS cut its price target to $195 in late February, and Barclays also reduced its target around the same period—actions that can weigh on sentiment even when ratings remain constructive. (marketbeat.com)

Investors are likely to focus on whether management commentary at conferences and upcoming quarterly updates point to stronger sequencing in the back half of 2026, particularly in franchises exposed to softer end-markets such as gene therapy-related demand. Any indication of faster order normalization, improved China trends, or better-than-expected operating leverage could shift the narrative; absent that, the stock may remain vulnerable to incremental de-risking on down days.